OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,580.00
+180.00 (2.43%)
At close: Jan 23, 2026
15.90%
Market Cap133.76B
Revenue (ttm)87.58B
Net Income (ttm)11.18B
Shares Out17.65M
EPS (ttm)731.00
PE Ratio10.37
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume450,817
Average Volume121,335
Open7,400.00
Previous Close7,400.00
Day's Range7,210.00 - 7,810.00
52-Week Range5,610.00 - 8,960.00
Beta0.37
RSI63.72
Earnings DateJan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 159
Stock Exchange KOSDAQ
Ticker Symbol 131030
Full Company Profile

Financial Performance

In 2024, OPTUS Pharmaceutical's revenue was 81.90 billion, an increase of 13.09% compared to the previous year's 72.43 billion. Earnings were 10.31 billion, a decrease of -4.20%.

Financial Statements